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Abstract
Purpose Recent studies from national registries have described changing patterns in epidemiology of acromegaly. Our ret-
rospective study used administrative databases to estimate prevalence and incidence of acromegaly in the Piedmont Region, 
Italy.
Methods This study was conducted in Piedmont between 2012 and 2016 on administrative health databases for inpatients 
and outpatients of any age. Enrollees were included if claims suggestive of acromegaly were identified in at least two of the 
following databases: Drug Claims Registry, Hospital Information System, Co-payment Exemption Registry and Outpatient 
Specialist Service Information System.
Results 369 individuals (M = 146, F = 223) met our criteria. Overall incidence was 5.3 per million person years (95% CI 
4.2–6.7), and prevalence was 83 cases per million inhabitants (95% CI 75–92). Mean age was 50.9 years. Both incidence and 
prevalence were slightly higher among women (rate ratio 1.08, prevalence ratio 1.43). Age-specific incidence was similar 
between sexes up to 39 years and diverged thereafter, with an increasing trend recorded among men. Prevalence was higher 
in women aged 40–79 years, and increased continuously up to 79 years in both sexes.
Conclusions This is the first population-based study conducted in Italy to estimate incidence and prevalence of acromegaly 
and results show a higher prevalence than previously reported. Although our algorithm requires proper validation, it consti-
tutes a promising tool to describe the epidemiology of acromegaly.
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Introduction
Acromegaly is a rare entity resulting from a growth hor-
mone (GH)-secreting pituitary adenoma [1]. The presenta-
tion and initial diagnosis of acromegaly can be insidious 
and, despite the advances in this field, there are significant 
diagnostic delays that could prompt adverse sequelae and 
influence the long-term disease prognosis. Hence, a timely 
diagnosis is desirable. To increase awareness on the disease, 
the Endocrine Society guidelines advised to screen for acro-
megaly in patients with typical clinical manifestations as 
well as in those without somatic signs but who carry sev-
eral typical comorbidities of acromegaly, such as obstructive 
sleep apnea, type 2 diabetes mellitus, debilitating arthritis, 
carpal tunnel syndrome, hyperhidrosis, and arterial hyper-
tension [2]. Similar recommendations were issued in the 
American Association of Clinical Endocrinologists (AACE) 
guidelines [3]. Another relevant issue is represented by ther-
apeutic millstones. GH-secreting pituitary tumors display 
a high prevalence of macroadenomas, which reduces the 
likelihood of complete surgical cure and prompts persistent 
disease in over 60% of cases [4–7]. In such instances, mul-
timodal therapies are necessary. Because these diagnostic 
and prognostic factors impact on the health care systems, it 
is important that optimal knowledge exists on chronic care 
activities related to acromegaly, including epidemiology, 
therapeutics and practices.
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Most epidemiological data currently available are 
extracted from data collected in specialized referral centers, 
whose catchment areas may not cover the whole popula-
tion. Published estimates have suggested highly variable 
figures encompassing prevalence rates of 28–137 cases per 
million and annual incidence rates of 2–12 cases per mil-
lion person years [3, 6, 8–15]. To improve accurateness in 
describing the epidemiology of acromegaly and its impact 
on healthcare systems [15], recent US studies have employed 
a novel analytical approach to derive estimates of incidence 
and prevalence based on data from population healthcare 
databases and insurance claims [13, 16, 17]. These recent 
epidemiological data collectively suggest that incidence and 
prevalence of acromegaly are rising [13, 17]. Uncertainty 
remains on whether this is the result of improved diagnostic 
tools, stricter clinical surveillance or temporal changes in 
incidence rates. The aim of our study was to estimate the 
prevalence and incidence of acromegaly in the Piedmont 
Region (Italy) through the analysis of routinely collected 
administrative data.
Methods
Data source
A retrospective cohort study was conducted using the 
Administrative Health Databases (AHDs) of Piedmont 
Region (about 4,400,000 inhabitants, corresponding to 
7.5% of the national population), from January 1, 2012 to 
December 31, 2016. Only data regarding patients residing in 
Piedmont were considered by employing a combined strat-
egy encompassing fiscal and health-related residential cat-
egories. Data were obtained from four different databases: 
(a) Drug Claims Registry, including records of all outpa-
tient drug prescriptions reimbursable by the National Health 
Service (NHS); (b) Hospital Information System, including 
records of all hospital discharge forms (HDFs) from public 
or private hospitals; (c) Co-payment Exemption Registry; (d) 
Outpatient Specialist Service Information System, reporting 
records of endocrine visits and healthcare services related to 
the workup of acromegaly provided by the NHS (laboratory 
and medical tests, outpatient visits, neuroimaging). These 
four databases can be linked through a unique identifier, 
which remains unchanged over time. The medical claims in 
HDFs included information on diagnoses reported according 
to the International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) diagnosis codes. Labo-
ratory and radiological data included information reported 
according to the National Tariff Nomenclature (NTN) codes.
Selection of cases
Potential cases were defined as the subjects who had claims 
suggestive of acromegaly in at least two of the four databases 
during the study period. The claims taken into account were:
1. Hospital discharge records with an acromegaly diagnosis 
code (ICD-9-CM: 253.0);
2. Exemptions from co-payment for acromegaly (code: 
001);
3. Prescriptions for any of the following medications: octre-
otide (ATC: H01CB02), lanreotide (ATC: H01CB03), 
pegvisomant (ATC: H01AX01), pasireotide (ATC: 
H01CB05);
4. Prescriptions for any of the following radiological tests: 
facial bone nuclear magnetic resonance (NMR) (codes 
88.91.3–88.91.4); cranial (sella turcica, orbit) computed 
tomography (CT) (codes 87.03–87.03.1).
To further improve the specificity of our approach, we did 
not take into considerations drug prescriptions if:
1. Patients had received less than three separate drug pre-
scriptions for the treatment of acromegaly (occasional 
drug users);
2. The medications were not long-acting release (LAR) 
formulations;
3. Patients taking octreotide or lanreotide had a hospitaliza-
tion with a diagnosis different from acromegaly, among 
those for which there is an indication for the use these 
drugs, as reported in the summary of product charac-
teristics (malignant neoplasms (ICD-9: 140–209, 230–
239), liver disorders (ICD-9: 570–573), gastrointestinal 
bleeding (ICD-9: 578), esophageal varices (ICD-9: 42), 
Cushing’s disease (ICD-9: 255; 255.0)
4. Patients had an exemption from co-payment for Cush-
ing’s disease (code: 032).
All procedures performed in this study were in accord-
ance with the ethical standards of the institutional and/or 
national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethi-
cal standards. The study protocol was approved by the local 
ethical committee of the “Maggiore della Carità” Hospital, 
Novara (CE 58/18). The study was performed using data 
routinely collected in the regional administrative health care 
databases and the authors had access only to anonymized 
data, so for this type of study informed consent was not 
required.
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Statistical analysis
Prevalence was calculated by dividing the number of preva-
lent cases of acromegaly (i.e., those with acromegaly-related 
claims at any time during the period 2012–2016) by the total 
number of residents in Piedmont. Incidence was calculated 
by dividing the number of new acromegaly cases (i.e., no 
evidence of acromegaly during the 2 years prior to the index 
claim) by the size of the population total time at risk dur-
ing the period 2014–2016. Incidence and prevalence esti-
mates were stratified by age (≤ 19, 20–39, 40–59, 60–79, and 
≥ 80 years) and sex. Comparisons of incidence and preva-
lence between the two sexes were carried out estimating 
rate ratios and prevalence ratios. Analyses were performed 
with the software Stata 12 (StataCorp, College Station, TX, 
USA).
Results
In the period 2012–2016, we found 369 individuals in the 
Piedmont population, 146 males and 223 females, who met 
our combined criteria for diagnosis of acromegaly. Incident 
cases in the period 2014–2016 were 71, of whom 33 were 
men and 38 were women. Mean age was 50.9 years. The 
observed number of cases translated into an incidence of 
5.3 per million per person years (95% CI 4.2–6.7) and a 
prevalence of 83 per million inhabitants (95% CI 75–92) 
(Table 1). When the index cases were stratified by sex, both 
the incidence and the prevalence were slightly higher among 
women. Compared to men, the rate ratio of women was 1.08 
(95% CI 0.67–1.72), while the prevalence ratio was 1.43 
(95% CI 1.16–1.76). Incidence rates were lowest among 
subjects with less than 19 years old. Age-specific incidence 
rates were similar in the two sexes up to the age of 39 years 
but seemed to diverge thereafter, with an increasing trend 
recorded among men compared to women (Fig. 1). Preva-
lence increased in both sexes continuously up to 79 years 
of age, and markedly decreased thereafter. Prevalence of 
acromegaly was substantially higher in women than men 
between 40 and 80 years of age (Fig. 2).
Discussion
This is the first population-based study conducted in Italy 
to estimate the prevalence and incidence of acromegaly in 
a geographically defined population, without the apparent 
limitations related to catchment area and referral practice. To 
do so, we developed an algorithm that identifies acromegaly 
cases combining information from four different adminis-
trative databases. This approach is similar to that adopted 
by Burton et al. [13] and Broder et al. [17], who used two 
large health insurance databases to estimate the incidence of 
acromegaly in the US. In addition to medical and pharmacy 
claims, however, our algorithm takes also advantage from 
information included in the Co-payment Exemption Registry 
and in the Hospital Information System, two reliable sources 
of data that have been previously used for epidemiological 
Table 1  Prevalence (period 2012–2016) and incidence (period 2014–
2016) of acromegaly in Piedmont Region (Italy), stratified by sex
Results expressed as cases per million person years (incidence) and 
cases per million inhabitants (prevalence)
Men Women
N Point estimate (95% 
CI)
N Point estimate (95% 
CI)
Incidence 33 5.1 (3.6–7.2) 38 5.5 (4.0–7.6)
Prevalence 146 68 (58–80) 223 97 (85–111)
Fig. 1  Incidence of acromegaly in Piedmont Region (Italy) in the 
period 2014–2016, stratified by sex and age groups
Fig. 2  Prevalence of acromegaly in Piedmont Region (Italy) in the 
period 2012–2016, stratified by sex and age groups
 Journal of Endocrinological Investigation
1 3
research in Italy. Our study showed an overall incidence of 
acromegaly of 5.3 cases per million person years, while the 
prevalence was 83 cases per million inhabitants. While the 
incidence of acromegaly here reported is comprised within 
the highly variable range of 1.9–7.7 cases per million person 
years found in European studies [9, 14, 18–24], two recent 
US surveys have reported an even higher incidence rate, cor-
responding to 9.6–11.7 cases per million person years [13, 
17]. The discrepancy of the results between the US and the 
European surveys could be due both to differences in study 
methodologies and to real differences in the incidence of 
the disease across the world. Mean age at the diagnosis of 
acromegaly in our study was 50.9 years and we observed 
an increasing trend of incidence with age, which is aligned 
with recent reports [15]. Although the overall incidence 
was similar between sexes, an age-specific analysis showed 
that trends of incidence were similar between sexes up to 
the age of 39 years but slightly increased in men thereafter, 
compared to women. These results are consistent with those 
obtained in the Swedish Pituitary Registry, which displayed 
an increasing trend for men and a decreasing one for women 
after the age of 35 years [21].
With regard to prevalence, we observed an increase 
with age in both sexes, leading to a peak in the age group 
60–79 years. Prevalence was higher in women than in men 
up to the age of 80 years, whereas the opposite was docu-
mented thereafter. The prevalence of 83 cases per million 
inhabitants found herein is higher than that of 60 cases per 
million recorded in a large Italian survey [25], as well as 
that obtained in past European studies [4, 19]. However, 
our estimates parallel the prevalence rates documented in 
more recent surveys [13, 14, 17]. Interestingly, an Ice-
landic survey found an even higher prevalence for acro-
megaly, reaching 121 cases per million inhabitants [23]. 
It is still a matter of debate whether incidence rates of 
acromegaly are increasing over time, and whether this is 
a real phenomenon or it is rather attributable to improved 
diagnostic techniques and disease awareness. Likely, the 
development of sensitive immunoassays for measuring GH 
and IGF-1 levels, as well as the widespread use of MRI for 
detecting small pituitary tumors, has increased the number 
of diagnoses of acromegaly over time [26]. In fact, many 
of the earlier studies were performed when neuroimag-
ing technology could only allow the identification of large 
tumors, while highest resolution and vast use of MRI now 
enables identification of pituitary masses that, previously, 
would have been too small to detect [27]. For this reason, 
incidentally discovered pituitary mass can be now identi-
fied in patients undergoing neuroimaging for unexplained 
headache, head injury workup, sinus disease, cervical 
spine disease, and vertigo. Once the diagnosis of pituitary 
mass is made, clinical evaluation often includes complete 
assessment of pituitary function to uncover an otherwise 
clinically silent disease [28]. Also, current diagnostic cri-
teria could have contributed to the increase of incidental 
diagnosis of acromegaly, as they no longer require the 
presence of typical phenotypic features of acromegaly [2]; 
moreover, in recent series no visible pituitary tumor on 
MRI was found, but the presence of GH-secreting pituitary 
adenoma of very small dimension was confirmed post-
surgical exploration [29]. Finally, increased awareness of 
the condition and its early manifestations may also have 
contributed to the apparent increase in disease prevalence.
Population-based design, definite regional enrollment, 
and multiple database sources are major strengths of our 
study. Results from this type of epidemiologic study are 
more generalizable than estimates derived from single-
institution studies or case series [15], and could partially 
compensate for the lack of national registries. Moreover, 
our study included all age groups, compared to other stud-
ies, capturing only commercially-insured patients under 
the age of 65 years [17]. A limitation of using claims 
data to estimate disease incidence is the inability to know 
with certainty that the first claim observed in the data 
corresponds to the first clinical diagnosis of the condi-
tion. Moreover, this approach cannot provide information 
on time from clinical diagnosis and disease status (e.g., 
active vs. inactive disease), as well as it lacks information 
on adenoma size, hormone levels, clinical stratification 
of subgroups, and cases of multiple endocrine neopla-
sia-1. Another potential limitation of the present study is 
the apparently short period of observation (2012–2016). 
However, similar time-confined methodologies have been 
employed for epidemiology purposes in other acromegaly-
related studies [13, 17], and are reckoned to appropriately 
reflect average epidemiology of the disease. Finally, but 
more importantly, our algorithm requires validation to 
constitute an effective tool.
In conclusion, this study provides a novel method to 
estimate the incidence and prevalence of acromegaly in 
the general population. Our results are consistent with 
the available literature on this topic and show a higher 
prevalence of acromegaly than previously reported. Even 
if our algorithm still requires proper validation, it repre-
sents a promising tool to describe the epidemiology of 
acromegaly, to assess its burden on patients and health 
care systems, and to provide guidance on resources allo-
cation, especially in countries lacking national registries 
of acromegaly. Future developments include the assess-
ment of time trends of the disease and the extension of the 
study to other Italian regions to evaluate the geographical 
heterogeneity.
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